Illinois HB4470 prohibits anticompetitive practices in pharmaceutical resolution agreements.
HB4470, the Prohibition on Anticompetitive Pharmaceutical Practices Act, aims to prevent anticompetitive practices in pharmaceutical resolution agreements. It defines "protected drug" as a pharmaceutical drug protected by a patent or federal law preventing approval of a competing drug. The Act presumes that a resolution agreement ending a dispute over an alleged patent infringement or protection violation has anticompetitive effects if it involves an item of value or limits a competing drug's research, development, or sale.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
Analyze for Free
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.